Inhibitor Therapeutics, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.089 USD | +0.03% | -26.20% | -3.26% |
03-29 | Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
-3.26% | 15.31M | |
+8.29% | 114B | |
+10.21% | 104B | |
-11.90% | 22.41B | |
+0.23% | 22.28B | |
-5.52% | 19.07B | |
-37.36% | 18B | |
-5.17% | 17.89B | |
+7.70% | 14.28B | |
+37.65% | 12.55B |
- Stock Market
- Equities
- INTI Stock
- News Inhibitor Therapeutics, Inc.
- Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt